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The later stages of cochlear differentiation and the developmental
onset of hearing require thyroid hormone. Although thyroid hor-
mone receptors (TRs) are a prerequisite for this process, it is likely
that other factors modify TR activity during cochlear development.
The mouse cochlea expresses type 2 deiodinase (D2), an enzyme
that converts thyroxine, the main form of thyroid hormone in the
circulation, into 3,5,3-triiodothyronine (T3) the major ligand for
TRs. Here, we show that D2-deficient mice have circulating thyroid
hormone levels that would normally be adequate to allow hearing
to develop but they exhibit an auditory phenotype similar to that
caused by systemic hypothyroidism or TR deletions. D2-deficient
mice have defective auditory function, retarded differentiation of
the cochlear inner sulcus and sensory epithelium, and deformity of
the tectorial membrane. The similarity of this phenotype to that
caused by TR deletions suggests that D2 controls the T3 signal that
activates TRs in the cochlea. Thus, D2 is essential for hearing, and
the results suggest that this hormone-activating enzyme confers
on the cochlea the ability to stimulate its own T3 response at a
critical developmental period.
deafness  thyroid hormone receptor
Thyroid hormone regulates many developmental processesthat vary in their tissue specificity and the stage at which they
occur. An important question therefore concerns the means by
which this systemic hormonal signal is able to elicit its specific
actions in a given tissue at the appropriate time. Hearing is one
of the most sensitive functions controlled by thyroid hormone,
and early-onset hypothyroidism or iodine deficiency are known
causes of deafness in humans and rodent model species (1–5).
Thyroid hormone is required for the timely coordination of a
complex set of differentiation events in the maturing cochlea. In
rodents, the cochlea is largely formed by birth, and it then
proceeds through a period of differentiation during which au-
ditory function initiates around postnatal day 13 (P13) and
matures by P20 (6, 7). Hypothyroidism during this period
retards the differentiation of the cochlea, including the epithe-
lium that contains the sensory hair cells (1, 3, 8, 9). The
mechanisms that prompt the progression of these developmental
events are poorly understood.
Thyroid hormone receptors TR and TR1 are ligand-
regulated transcription factors and are expressed in the sensory
epithelium and other tissues in the rodent cochlea from midg-
estation into the postnatal period (10, 11). TR-deficient mice
display auditory deficits with a subset of hypothyroid-like ab-
normalities in the cochlea (12, 13). TR1 is individually dis-
pensable for hearing, whereas deletion of both TR and TR1
produces exacerbated defects that resemble those caused by
hypothyroidism (13–15). Some human TR mutations are as-
sociated with hearing loss (16–18). Although TRs are necessary
mediators of thyroid hormone signaling, it is unclear which other
factors influence TR activity during cochlear development.
Thyroid hormone may be metabolically activated or inacti-
vated by iodothyronine deiodinases (19–21). Thyroxine (T4), the
main product released by the thyroid gland into the circulation
is converted by outer ring 5-deiodination into 3,5,3-
triiodothyronine (T3) the principal ligand of the TR. This
conversion is mediated by deiodinase type 2 (D2) and deiodinase
type 1 (D1) encoded by Dio2 and Dio1, respectively. Deiodinase
type 3 (D3) depletes tissues of active hormone by inner ring
deiodination of T4 and T3. The differential expression of D1,
D2, and D3 in some tissues (22–26) raises the possibility that
deiodinases play specific developmental roles. Previously, we
identified prominent expression of D2 in the early postnatal
mouse cochlea, suggesting a role for D2 in the development of
hearing (27). D2 is expressed in the cochlear capsule and
connective tissues that surround the internal sensory tissues.
Here, we report an essential role for D2 in the development of
the auditory system.
Methods
Mouse Strains. The targeted deletion of Dio2 was carried on a
mixed background of 129SvJ  C57BL6 strains, as described
(28). The mutation was backcrossed for two further generations
onto the C57BL6J strain (The Jackson Laboratory, no. 000664)
that has minimal hearing loss before 6 months of age (13, 29).
Genotyping was performed on genomic DNA by PCR with
primers specific for neo in the Dio2 mutant allele and for a
region of intron 1 and exon 2 specific for the WT gene (GenBank
accession no. NT039552). Primer sequences were: neo sense and
antisense, GTGTTCCGGCTGTCAGCGC and GTCCTGAT-
AGCGGTCCGCCA, respectively; and Dio2 sense and anti-
sense, GACCATCCTTTATATTGCCTGACATG and GGCG-
GAAGGCTGGCAGTTGCC, respectively. Dio2/ and control
littermates were derived from crosses of Dio2/ parents or
Dio2/ male and Dio2/ females. Nursing dams or pregnant
dams at 14.5–17.5 days postcoitum were treated with 0.3 or 1.0
gml L-triiodothyronine (Sigma) in drinking water. Animal
studies were conducted under approved protocols at Mount
Sinai School of Medicine and Dartmouth Medical School.
Statistical analyses were performed by using the Student t test.
Auditory-Evoked Brainstem Response (ABR). The ABR was mea-
sured by using a SmartEP system (Intelligent Hearing Systems,
Miami) as described (13, 29). Mice were anesthetized with
avertin (0.25 mgg of body weight) for the short duration of the
test and on revival were returned to their cages. Stimuli were
presented at a rate of 25s and averaged across 512 sweeps.
Responses were bandpass filtered 100 and 3,000 Hz and
amplified 100,000-fold. A threshold was defined as the minimal
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stimulus level that gave a recognizable waveform on a normal-
ized scale. For presentation in figures, a fixed scale is used.
Histology, Immunohistochemistry, and Electron Microscopy. Co-
chleae were fixed in 3% glutaraldehyde2% paraformaldehyde,
decalcified, embedded in methacrylate, sectioned at 3–5m, and
stained with thionin, as described (13). Groups of four to six
cochleae from three mice were analyzed. Cryosections made
from paraformaldehyde-fixed tissues were immunostained with
antibodies against - and -tectorins by using detection with
FITC-conjugated secondary antibodies (30). Tectorial mem-
brane (TM) ultrastructure was examined in ultrathin sections by
transmission electron microscopy, as described (13), in WT and
Dio2/ mice (n  3) at 1 month of age. Prior analysis of ABR
thresholds confirmed the auditory phenotype of these mice: WT,
42 	 2 dB sound pressure level (SPL); Dio2/ mice, 73 	 3 dB
SPL for a click stimulus.
Deiodination Assays and Hormone RIAs. For each genotype, three
pools of cochleae each from 20 pups at P8 were collected on
dry ice before assaying D2 and D3 activity, as described (28).
Cochleae were homogenized in assay buffer containing 0.25 mM
sucrose, 20 mM TrisHCl, pH 7.6, with 5 mM DTT. For D2
assays, the mixture (total volume 50 l) contained 80–100 g
of tissue protein and 1.2 mM EDTA. Substrate was 1.0 nM of
[125I]reverse T3 or [125I]T4, and cofactor was 20 mM DTT.
Reactions were incubated for 1 h at 37°C in the presence or
absence of 1 mM 6-n-propyl-2-thiouracil, a D1 inhibitor, and the
[125I]I generated was detected after separation by ion exchange
chromatography on Bio-Rad AG 50WXG (H) resin. For D3
assays, the mixture did not contain EDTA, substrate was 1.0 nM
[125I]T3, and cofactor was 50 mM DTT; products were separated
for analysis by paper chromatography. [125I]reverse T3, [125I]T4,
and [125I]T3 (specific activities 1,000 Cig) were obtained
from Perkin–Elmer and purified by chromatography using Seph-
adex LH-20 (Sigma) before use. Total T4 and total T3 levels were
determined by RIA using Coat-A-Count reagents (Diagnostic
Systems Laboratories, Webster, TX) (28) or a chemiluminescent
assay for T4 on an Advia Centaur instrument (Bayer Health-
Care, Tarrytown, NY) and a fluorometric assay for T3 on an
Abbott AxSYM instrument. Coefficients of variation were
6–10% for T4 and 5–13% for T3.
Northern Blot Analysis. Total RNA samples from pools of cochleae
from P8 pups (30 per genotype) were analyzed with a glycer-
aldehyde-3-phosphate dehydrogenase probe and a 1.4-kb mouse
D2 cDNA probe (B1), extending from the fifth codon to 561 bp
downstream of the stop codon in the 3 untranslated sequence,
as described (27).
Results
Auditory Deficits in Dio2/ Mice. Dio2/ mice are a suitable
model for the analysis of auditory function as they lack gross
developmental defects (28, 31). The deletion in the major coding
exon of Dio2 (28) allowed mice to be genotyped by PCR, as
shown in Fig. 1A. Northern blot analysis detected a 7.0-kb D2
mRNA in cochlear samples from WT and Dio2/ pups but not
from Dio2/ pups (Fig. 1B). Normally, cochlear D2 activity
rises during the first postnatal week and is abundant at P8 (27).
Cochlear homogenates from Dio2/ pups at P8 lacked 5-
deiodinase activity, assayed with T4 or reverse T3 substrates
(Fig. 1C). Activity was reduced by 50% in Dio2/ mice. The
5-deiodinase activity displayed by WT and Dio2/ samples was
attributable to D2 because it was not significantly different in the
presence or absence of propylthiouracil, an inhibitor of D1. Inner
ring deiodination by D3 was detected at similar low levels in
cochlear samples from WT, Dio2/, and Dio2/ pups at P8.
Thus, no compensatory changes in D1 or D3 were evident in the
cochlea in Dio2/ mice.
To rule out systemic hypothyroidism in development as a
cause of any deafness, thyroid hormone levels were determined
in serum of WT and Dio2/mice between P8 and P25 (Fig. 1D).
Dio2/ pups displayed moderately elevated T3 and T4 levels,
whereas Dio2/ adults, as reported previously, had slight T4
increases caused by a mild dysfunction of the pituitary–thyroid
axis (28). The degree of elevation of T4 and T3 was greater in
younger Dio2/ pups but moderated by P16. Thus, no general
deficiency of thyroid hormones occurred in Dio2/ mice.
Hypothyroidism presents a known risk to hearing but a modest
thyroid hormone increase would not cause overt deafness (12,
32) (and see Fig. 5).
Fig. 1. Inactivation of cochlear D2 in Dio2/ mice. (A) Dio2/, Dio/, and
WT genotypes determined by PCR, based on the deletion in coding exon 2 in
the mutant allele. Origins of primers specific for the mutant (neo) and WT
alleles are indicated by arrowheads; sizes of products are indicated on the left
(in bp). (B) Northern blot analysis of cochlear total RNA (15 g per lane) from
P8 pups detected a major 7-kb D2 band only in Dio2/ and Dio2/ mice. A
glyceraldehyde 3-phosphate dehydrogenase (G3PDH) control probe was used
on the same blot. (C) D2 5-deiodinase activity in cochlear homogenates from
P8 mice assayed with T4 or reverse T3 substrates. Activity was undetectable in
Dio2/ samples, and in Dio2/ mice it was 50% below WT levels (*, P
0.05). Results were similar in the presence or absence of propylthiouracil
(PTU), an inhibitor of D1. D3 activity was detected at similar, low levels in all
genotypes. (D) Serum levels of total T4 and total T3 during development in
Dio2/ and WT mice. In Dio2/ mice, T4 was somewhat elevated and T3 was
normal or slightly elevated.
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To assess hearing, the ABR was measured in WT, Dio2/,
and Dio2/ littermates. Responses were markedly impaired in
all Dio2/ mice and could be evoked only with a significantly
increased SPL (Fig. 2A). In 1-month-old Dio2/ mice, the mean
threshold for a click stimulus was 79 	 2 dB SPL, an increase of
40 dB above normal (WT, 39 	 2 dB SPL; P0.001), indicating
a severe, although not total, impairment of auditory function.
ABR waveforms in mice typically display four to five peaks with
the first two to three peaks representing responses from the
cochlea and proximal brainstem centers (29, 33). In Dio2/
mice, all peaks were poorly defined and had prolonged latency
(Fig. 2B). Using a click stimulus at 90 dB SPL, mean latencies to
peak IV in WT, Dio2/, and Dio2/ mice were 4.06 	 0.21,
4.44	 0.05, and 5.75	 0.19 ms, respectively (n 6–8; P0.001
for Dio2/ vs. WT or Dio2/). The ABR also showed elevated
thresholds and poorly defined waveforms in Dio2/ mice for 8-,
16-, and 32-kHz stimuli that span the sensitive hearing range of
mice. Similar threshold increases were recorded in 3-month-old
Dio2/ mice, indicating a permanent defect (for a click stim-
ulus; thresholds were 81	 1 and 42	 3 dB SPL, for Dio2/ and
WT mice, respectively; P0.01; n 8 Dio2/, n 4 WT). The
auditory defects in Dio2/ mice were similar to or slightly worse
than those in TR-deficient mice (12, 13).
Abnormal Cochlear Morphology in Dio2/ Mice. Histological anal-
ysis in Dio2/ mice revealed retarded differentiation of the
cochlear inner sulcus and sensory epithelium and deformity of
the TM, a secreted extracellular matrix that is necessary for the
response of the mechanosensitive hair cells to sound stimulation
(30). The defects detected in Dio2/ mice resided in known
thyroid hormone-sensitive tissues in the cochlear interior rather
than in the surrounding connective tissues that normally express
D2 (i.e., the cochlear capsule, the septal divisions between the
turns of the cochlea, and the modiolus) (27).
Normally at P8, the sensory epithelium forms three distinct
rows of outer hair cells and one row of inner hair cells separated
by the tunnel of Corti, whereas the inner sulcus epithelium is
partly retracted below the TM (Fig. 3A). In the adult, the TM
extends fully across the cavity of the inner sulcus to contact the
stereociliary bundles of the hair cells (Fig. 3D). In Dio2/ pups
at P8, the sensory epithelium was poorly differentiated, the
tunnel of Corti was unopened, and the inner sulcus was only at
an early stage of formation (Fig. 3B). The inner sulcus epithe-
lium was thicker with taller columnar cells than in WT pups. The
TM was enlarged and attached for most of its length to the
underlying epithelium. Occasionally, the TM was thinner and
the inner sulcus was partly developed, suggesting variable pen-
etrance for part of the phenotype (Fig. 3C). However, all Dio2/
pups showed retarded differentiation of the sensory epithelium.
The TM enlargement was evident as early as P4 but other
morphological changes were not observed before P4 in Dio2/
mice.
In adult Dio2/ mice, the differentiation of many features of
the sensory epithelium and the opening of the tunnel of Corti
had progressed to resemble the WT cochlea. The TM, however,
remained variably malformed (Fig. 3E). The TM deformity was
Fig. 2. Defective auditory function in Dio2/ mice. (A) Mean ABR thresholds	SEM in 1-month-old mice. Dio2/ and Dio2/ mice had normal thresholds for
a click stimulus (a broadband of frequencies from 2 to 20 kHz) and pure tones of 8, 16, and 32 kHz. Dio2/mice had elevated thresholds for all stimuli (P0.001).
(B) Representative ABR waveforms for a click stimulus, shown on a 4-V fixed scale. Thresholds are underlined. Normally, four main peaks (marked I–IV) were
detected within 5 ms of stimulation (a fifth peak is often not discernible in mice). In Dio2/ mice, waveforms were poorly defined with reduced amplitude and
prolonged latency (assignment of specific peak numbers was precluded in some Dio2/ mice because of this poor definition).
Fig. 3. Cochlear morphology in Dio2/ mice. (A–C) P8 pups. (A) In the WT,
the tunnel of Corti (TC) has opened between the pillar cells adjacent to the
inner (filled arrowhead) and outer (three open arrowheads) hair cells. The TM
is thin and extends over the inner sulcus (IS). (B) In this Dio2/ pup, the TM is
enlarged and attached to the underlying epithelium; the inner sulcus epithe-
lium (ISE) is thick; the sensory epithelium, containing the hair cells, is poorly
differentiated; and the TC is absent (arrow). (C) A Dio2/pup, in which the TM
is more normally shaped, but differentiation of the ISE and sensory epithelium
is still retarded and the TC is absent (arrow). (D–F) Adults. (D) A WT cochlea,
with mature formation of the TC, outer tunnel (OT), inner sulcus, and TM. (E)
In this Dio2/ cochlea, differentiation of the ISE and sensory epithelium has
progressed to resemble the WT but the TM is still mildly enlarged. (F) This
Dio2/ cochlea exhibits a grossly malformed TM and degeneration or
aborted differentiation of the ISE and sensory epithelium (below asterisks).
(Scale bars: 50 m for all.)
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usually slight in adults although Fig. 3F shows an extreme
example with a severely malformed TM and disorganization of
the sensory epithelium, indicating degeneration or aborted
development of these tissues.
The ultrastructure of the TM in Dio2/ mice was also
abnormal. The normal TM contains a series of major collagen
fibrils embedded in a striated sheet matrix of fine filaments (Fig.
4A) (34). In Dio2/ mice, the major fibrils were present but the
striated sheet matrix was disorganized in the middle and upper
regions of the TM (Fig. 4B). The matrix, however, was normal
in lower regions of the TM lying closest to the inner sulcus. The
TM still contained the major - and -tectorin glycoproteins as
found in WT mice (Fig. 4C) (30). This finding suggests, that as
in TR-deficient mice, the lack of D2 does not block expression
of TM components but instead may impair their assembly or
processing. The cochlear defects in Dio2/ mice and the TM
deformity with a partial disorganization of ultrastructure closely
resembled the phenotype in TR-deficient mice. The TM ab-
normalities, however, were milder than in mice lacking both TR
and TR1, in which ultrastructural disorganization occurred
throughout all regions of the TM (13).
Recovery of Auditory Sensitivity by T3 Administration. The auditory
phenotype in Dio2/mice was remarkably similar to that caused
by hypothyroidism despite the fact that Dio2/ mice possess
serum levels of T4 and T3 that would normally be adequate for
the development of hearing. This finding suggests that D2 is
required to generate T3 in the auditory system above levels
available in serum in postnatal development. Therefore, we
tested whether T3 supplementation could overcome such a local
T3 insufficiency in Dio2/ mice. T3 was added at different
starting points to the drinking water of nursing Dio2/ dams or
weaned progeny until P28 when the ABR was measured. Treat-
ment from P10 with 0.3 gml T3 resulted in 2- to 5-fold
increases in serum T3 when measured at P16 (Fig. 5B). After
weaning at P21, mice that ingested T3 directly had 8- to 12-fold
increased serum T3 levels (n  8).
T3 given from P10 improved the mean ABR thresholds by30
dB SPL in Dio2/ mice compared to untreated Dio2/ mice
(Fig. 5A). The improvement was nearly complete in most
Dio2/ mice although 30% showed only a limited recovery. A
lesser degree of correction was achieved when T3 was given later.
Treatment of Dio2/ pups from P16 improved ABR thresholds
by 10 dB SPL, whereas treatment from P23 did not correct
thresholds. T3 treatment of Dio2/ mice also enhanced the
definition of the waveform (Fig. 5C and see untreated example
in Fig. 2B) and improved its latency (with T3 treatment from
P10, peak IV latency was shortened from 5.75 	 0.19 to 4.87 	
0.31 ms; n  8; P 0.01). Thresholds were in the normal range
in Dio2/ or WT controls regardless of treatment.
Higher T3 doses produced systemic toxicity but paradoxically
still improved ABR thresholds. T3 treatment (1 gml) begun in
utero retarded body growth of Dio2/ pups, which attained
60% of untreated weight at weaning (at P22, Dio2/ female
treated, 5.8	 1.2, untreated 9.6	 0.4 g; male treated, 4.9	 1.0,
untreated 9.2	 0.7 g; n 4–6; P0.001). Mice in these treated
groups showed 30 dB SPL improvements in ABR thresholds
compared to untreated Dio2/ mice (n  14; P 0.001),
although 30% (4 of 14) had only slight improvement. Treatment
of Dio2/ control mice from embryonic stages, but not from
P10 or later, also resulted in some progeny (3 of 12) acquiring a
defective ABR. These findings suggest that the embryonic or
neonatal auditory system is susceptible to impairment by exces-
sive T3 regardless of genotype. The improvement of auditory
sensitivity by T3 administration identified a T3 deficiency as the
critical defect underlying the deafness in Dio2/ mice, in accord
with the activity of D2 in generating T3.
T3 treatment also improved cochlear differentiation in
Dio2/ mice. In untreated Dio2/ mice at P16 (Fig. 5D),
differentiation had progressed from the immature state shown at
P8 in Fig. 3B to form distinct hair cells and an open tunnel of
Corti. However, the inner sulcus epithelium adjacent to the inner
hair cells was thicker with a denser array of columnar cells than
in Dio2/ pups and the TM remained malformed. In Dio2/
pups treated with T3 from P10 until analysis at P16, morphology
more closely resembled the normal state for that stage of
development with a better differentiated inner sulcus epithelium
Fig. 4. TM defects in Dio2/ mice. (A) Transmission electron microscopy
reveals the normal ultrastructure of a midregion of the TM, which contains
major collagenous fibrils (arrowheads) and a fine, striated sheet matrix (par-
allel arrows in Inset). WT mouse, at P28. (B) In Dio2/mice, the major collagen
fibrils are present (arrowheads) but the fine filaments of the matrix are
disorganized (arrows in Inset) in middle and upper regions of the TM (most
distal to the inner sulcus). Small boxes indicate areas that are enlarged 3-fold
in the Inset. (C–F) Immunofluorescent detection of tectorin components of the
TM in WT (C and E) and Dio2/ (D and F) pups at P8. Note TM enlargement in
Dio2/ mice (arrowhead). (Scale bars: 200 nm for A and B; 50 m for C–F.)
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and thinner TM (Fig. 5E). T3 treatment did not produce obvious
abnormalities in Dio2/ control pups (Fig. 5 F and G).
Discussion
This study reveals that D2 is essential for the development of
hearing. The similarity of the cochlear phenotypes caused by D2
or TR deficiency suggests that D2 controls the T3 signal in the
cochlea to activate the TR at a critical phase of development. On
a comparative scale, the auditory phenotype in Dio2/ mice is
slightly worse than in TR-deficient mice but is milder than that
caused by deletion of both TR and TR1 (13) or by severe
systemic hypothyroidism (1). The differences in severity may be
explained if the normal to slightly increased levels of circulating
T3 in Dio2/ pups provide small amounts of ligand that
stimulate limited activity by TR and TR1 in the cochlea. In
contrast, systemic hypothyroidism or the deletion of all TRs
would cause a more absolute block of thyroid hormone signaling.
The variable severity of some features of the Dio2/ phenotype
is consistent with the enzymic role of D2 in generating subtle T3
fluxes in the cochlea, which may be expected to vary somewhat
among individuals.
Why is the development of the auditory system so dependent
on D2 and why would the maturing cochlea in effect stimulate
its own response to thyroid hormone? The finding that normal
or marginally increased serum levels of T3 are inadequate for the
demands of the cochlea supports the role of D2 as a tissue-
specific amplifier of T3 action. Thus, D2 would draw on the T4
supply in serum and convert this into T3 at the necessary stage
of development. The demands for T3 in the postnatal cochlea
may be considerable given the range of differentiation events
that require thyroid hormone in the inner sulcus, sensory
epithelium, spiral ganglion, and auditory nerve and in the
formation of the TM (1, 3, 11, 13, 15). D2 may have other
functions in central auditory pathways because D2 mRNA is also
expressed widely in the brain, including in central auditory
regions (24). Indeed, the poor overall definition and prolonged
latency of the ABR waveform in Dio2/ mice raises the
possibility that defects exist not only in the cochlea but also in
the auditory nerve and brainstem auditory regions. Further
study is necessary to determine whether there is any type of brain
defect in Dio2/ mice. The improvement of auditory sensitivity
by high T3 doses that otherwise retard body growth in Dio2/
pups emphasizes the differential demands of the auditory and
other systems for T3 at certain developmental stages. Thus, the
local amplification of the hormonal signal by D2 would provide
an efficient means of coordinating multiple developmental
events in the maturing auditory system. Moreover, the location
of D2 in the auditory system itself may confer immediacy in
prompting the timely maturation of this sensory system.
The results suggest that T3 signaling regulates not only the
onset of auditory function but also the subsequent maturation of
auditory sensitivity. The maturation of auditory function in
rodents occurs over a protracted period lasting untilP20 (6, 7).
A continuing role for D2 over this period would explain why T3
administration begun as late as P16 partly improves auditory
sensitivity in Dio2/ mice. Possibly, some functions are simply
arrested and the later provision of T3 is able to reactivate these
differentiation events. The chambered structure of the cochlea
points to the likelihood that D2 function is integrated with
currently unknown mechanisms that would transport specific
forms of thyroid hormones across the compartments of the
cochlear microenvironment. A paracrine-like action of thyroid
hormone may therefore operate involving T4 uptake, the gen-
eration of T3 by D2, and the release of this T3 to stimulate
responsive tissues in the cochlear interior.
D3, a thyroid hormone-inactivating enzyme, has been shown
to regulate Xenopus eye development, probably by reducing local
levels of thyroid hormone in the dorsal retina (25). Our results
suggest that the hormone-activating D2 enzyme provides an
equally potent developmental control but through an opposite
mechanism of amplifying T3 action. Thus, both enzymes may
promote critical tissue-specific variations in local T3 levels in
development. Somewhat analogously, the enzymes that synthe-
size and degrade retinoic acid are thought to control the activity
of retinoid receptors (35). The findings in Dio2/ mice suggest
Fig. 5. T3 recovers auditory sensitivity in Dio2/ mice. (A) Mean ABR
thresholds	SEM in mice at P28 after T3 treatment starting at P10, P16, or P23.
Untreated groups are shown in columns marked . T3 was given in drinking
water (0.3 gml) to nursing dams and weaned progeny. Compared to un-
treated mice, thresholds were substantially corrected in Dio2/ progeny
when treatment started at P10 (P  0.002), partly corrected when started at
P16 (P 0.005), and not significantly corrected when started at P23 (P 0.06).
Similar results were obtained for 8-, 16-, and 32-kHz stimuli. (B) Serum levels
of total T3 and total T4 in P16 pups after T3 treatment (0.3 gml) from P10.
Treatment (T3) increased T3 levels 2- to 5-fold over untreated levels (T3).
As expected, T3 treatment also suppressed the function of the pituitary–
thyroid axis, thereby reducing T4 levels. Groups contained two pools of serum
from 16–20 pups except for the T4 assays in T3 groups, which contained
single pools of serum from n 5–8 pups. (C) The thresholds and definition of
ABR waveforms were improved in Dio2/ mice when treated from P10, but
were less improved when treated from P16 and not improved when treated
from P23. Thresholds are underlined. Traces are shown on a 4-V fixed scale.
(D–G) Improved cochlear morphology in Dio2/mice after T3 treatment from
P10 until analysis at P16. In untreated Dio2/ pups (D), the TM is malformed
and the inner sulcus epithelium (ISE) is thicker with taller, columnar cells than
in untreated Dio2/ pups (F). T3 improved ISE differentiation and the shape
of the TM in Dio2/ pups (E) but did not obviously alter morphology in
Dio2/ control littermates (G). Inner and outer hair cells are marked by black
and white filled arrowheads, respectively, in D. Sections show comparable
apical turns of the cochlea. Groups, n  3. (Scale bar: 50 m for D–F.)
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that the amplification of thyroid hormone action in the target
organ itself provides an important developmental control in the
auditory system.
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